Speakers

Expand/Collapse

Amr Abdeen
Postdoctoral Associate
University of Wisconsin- Madison

Discussion Day

2:00 pm | Improved Non-Viral Vectors for In Vivo Genome Editing

Omar Abudayyeh
McGovern Fellow
Harvard University

Day Two

Thursday May 21 2020

8:30 am | Harnessing Novel CRISPR Tools for Genome Engineering and RNA Editing

Alejandro Amador
Head of High Throughput Biology, Functional Genomics
GlaxoSmithKline

Andrew Anzalone
Postdoctoral Fellow
Liu Group, Broad Institute

Day One

Wednesday May 21 2020

8:30 am | Exploring the Potential of Prime Editing

Luis Barrera
Head of Computational Sciences
Beam Therapeutics

Day Two

Thursday May 21 2020

1:30 pm | Comprehensive Identification of Base Editor Off-Targets in the Context of Therapeutically Relevant Delivery

12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?

Carsten Charlesworth
Graduate
Stanford University

Day Two

Thursday May 21 2020

4:00 pm | Utilizing CRISPR to Grow Human Organs for Transplantation

Delai Chen
Associate Director, Nanoparticle Formulation
Beam Therapeutics

Discussion Day

12:15 pm |

Paul Diehl
Chief Operating Officer
Cellecta

Day One

Wednesday May 21 2020

11:30 am | Functional CRISPR Screening and Cell Barcoding to Identify Genes Driving Biological Responses and Disease Progression

Rafi Emmanuel
Research Director
Emendo Biotherapeutics

Day One

Wednesday May 21 2020

2:30 pm | Target Optimized Variant of CRISPR Associated Nuclease Enables Allele-Specific Knock Out of ELANE-Related Neutropenia

Jonathan Gootenberg
McGovern Fellow
Harvard University

Day Two

Thursday May 21 2020

10:30 am | CRISPR Diagnostics: Expanding the Nucleic Acid Detection Toolbox by Harnessing Microbial Diversity

Julian Grunewald
Research Fellow
Joung Lab, Massachusetts General

Day One

Wednesday May 21 2020

9:00 am | Developing and Improving Base Editors

Killian Hanlon
Research Fellow
Harvard University

Discussion Day

10:15 am | Overcoming Limitations of Viral Vectors to Deliver CRISPR Machinery

Ben Kleinstiver
Principal Investigator
Massachusetts General

Day Two

Thursday May 21 2020

11:30 am | Broadly Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties

Sanne Klompe
Graduate
Sternerg Lab, Columbia University

Day One

Wednesday May 21 2020

11:00 am | Utilizing CRISPR-Associated Transposons for Programmed Insertions Without Generating Double-Strand Breaks

Kunwoo Lee
Chief Executive Officer & Co-Founder
GenEdit

Discussion Day

12:15 pm |

11:45 am | Non-Viral Delivery of CRISPR Using Polymer Nanoparticles

Blair Madison
Senior Director, Genetic Engineering
Poseida Therapeutics

Day Two

Thursday May 21 2020

2:00 pm | Creating Novel Proteins to Optimize Efficacy and Specificity

12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?

Ana Moreno
Founder & Chief Executive Officer
Navega Therapeutics

Day Two

Thursday May 21 2020

9:00 am | Epigenome Editing using CRISPR to Treat Pain

Niren Murthy
Professor
University of California at Berkeley

Discussion Day

11:15 am | Gene Editing After Local Injection: Non-Viral Delivery

Kiran Musunuru
Principal Investigator
Harvard University

Day Two

Thursday May 21 2020

2:30 pm | Applying CRISPR to Predict and Treat Cardiovascular Disease

Kalina Paunovska
Postdoctoral Fellow
Dahlman Lab, Georgia Tech

Discussion Day

2:30 pm | Delivering CRISPR Apparatus In Vivo Using Nanoparticle Technology

Karl Petri
Research Fellow
Joung Lab, Massachusetts General

Day One

Wednesday May 21 2020

3:30 pm | ONE-seq: Detection of CRISPR Nuclease and Base Editor Off-Targets with Ultra-High Sensitivity to Ensure the Safety of CRISPR Therapeutics

Sicco Popma
Founder, Chief Executive Officer & President
IO Biosciences

Day Two

Thursday May 21 2020

3:30 pm | Developing CRISPR-Based Cell Therapies Using a Proprietary Gene Editing System (GEMS)

Satinder Rawat
Senior Licensing Officer
University of Massachusetts

Day One

Wednesday May 21 2020

2:00 pm | Bridging the Gap Between Academia and Industry: Translating Cutting-Edge Technologies from the Lab to the Clinic

David Schaffer
Co-Founder
4D Molecular Therapeutics

Discussion Day

9:45 am | Directed Evolution of Novel AAV Variants for Clinical Gene Therapy

Brett Staahl
Founder & Head of Applied Technologies
Scribe Therapeutics

Discussion Day

9:15 am | Why Isn’t the Future of Medicine Here Yet?

Marija Tadin- Strapps
Vice President, Exploratory Biology
SQZ Biotechnologies

Discussion Day

3:00 pm | CellSQZ platform for Development of Next Generation Cell Therapies

Fyodor Urnov
Scientific Director
Innovative Genomics Institute

Day One

Wednesday May 21 2020

4:30 pm | Chair’s Closing Remarks

8:00 am | KEYNOTE: CRISPR 2030: the Promise and the Challenge

7:50 am | Chair’s Opening Remarks

Rui Wang
Principal Research Scientist
Abbvie

Renee Wegrzyn
Program Manager
DARPA

Day Two

Thursday May 21 2020

11:00 am | Programmable Gene Modulation

Carlo Zambonelli
Associate Director
Beam Therapeutics

Day One

Wednesday May 21 2020

4:00 pm | Developing Assays and Tools for Base Editing

Kate Zhang
Vice President, Biological Development
Editas Medicine

Day One

Wednesday May 21 2020

11:50 am | Optimizing CRISPR/Cas to Translate Efficiently into the Clinic

Lihua Julie Zhu
Professor & Head of Bioinformatics Core
University of Massachusetts

Speaker to be Confirmed

Aldevron

Day One

Wednesday May 21 2020

1:45 pm | Slot Reserved for Aldevron